Ironwood PharmaIRWD
NASDAQPharmaceuticals
No cached AI snapshot yet for IRWD.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
100 employees163.06M shares outstandinglisted 2010-02-03
Next earnings ~May 5, 2026
About Ironwood Pharma
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Latest News
Showing market-wide stock news
Treasury ETF shorts shift toward belly ahead of Fed decision
BoE to 'stand ready to hike', committee remains 'deeply divided'
The Fed’s interest rate decision in the epicenter of attention
News Flash: 70% of Wall Street Institutions Are Calling for at Least a 50-Basis-Point Fed Rate Hike in 2026
Nifty holds above 23,250 level; European shares trade mostly in green
The Stock Market Is Sending a Rare Historical Warning. Warren Buffett Says Investors Should Make This 1 Move.
Related Stocksin Pharmaceuticals
Ready to see the live AI view on IRWD?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing IRWD side-by-side with live signals.